Clinical Research Active Clinical Trials Nationally There have been significant research advances in the fields of haemtopoetic stem cell transplantation and cellular therapies which is reflected in the increasing number of available industry sponsored and investigator initiated clinical trials in these fields. For an accurate and up to date list with contact details of your local clinical trials please refer to the ClinTrials Refer website or app. New South Wales Assure Study A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide. Autoimmune disorders A single centre Phase II Study of Haematopoietic Stem Cell Transplantation for Severe Auto-Immune Diseases BREEZE A Randomized, Double -blind, Multicentre Study to Evaluate the Efficacy and Safety of ALX 01717 versus Placebo, in Addition to Standard of Care, in Adults, Who have Undergone Hematopoietic Stem Cell Transplantation and Present with Respiratory Syncytial Virus Respiratory Tract Infection CAPILANO A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation. COMITTAL Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell transplant for Acute Leukaemia with CD34+ selected stem cells. CYP-001 An Open- Label Phase 1 Study to investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults with Steroids-Resistant Acute Graft Versus Host Disease. INCB 39110-301 / GRAVITAS A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease HAPLO BMT A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis INTACT-WT1 A clinical trial of Donor-Derived WT1 Specific T Cells for Prevention of Relapse in Combination with Multiple Pathogen Specific T cells for Prevention of Infection in Patients Undergoing Allogeneic Haemopoietic Stem Cell Transplant for AML. MORPHO A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML MSC STUDY A phase 2 trial of standard of care treatment versus mesenchymal stromal cell therapy together with standard of care treatment for the treatment of de novo grades 2-4 acute graft versus host disease following allogeneic bone marrow transplantation PCYC-1140-IM A randomized, double blind phase 3 study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New onset Chronic Graft Versus Host Disease. PK Busulphan Pharmacokinetics, pharmacodynamics and pharmacogenomics, of Buslphan and other agents used in blood or marrow transplantation. REACH 2 A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation REACH 3 A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3) REACT quickly Therapeutic infusion of most closely related HLA-matched third party donor-derived virus specific cytotoxic T-lymphocytes in patients with previously untreated viral infection post allogeneic stem cell transplantation. The CARTELL Study A phase I study of CD19 specific chimeric Antigen Receptor T-Cells for Therapy for Persistent and Relapsed B-Cell leukaemia and lymphoma post allogeneic stem cell transplantation. Victoria and Tasmania CAPILANO A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation. CAST (ALLG BM12) Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. HAPLO BMT A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis INTEGRATE Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE) MORPHO A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML NIVALLO Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation REACH 2 A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation REACH 3 A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3) ROYAL BRIS TCZ A phase III randomized study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post Human Leuckocyte Antigen (HLA)-matched allogeneic haematopoietic progenitor cell transplantation (HPCT) Queensland IMPECT A multi-center, prospective, exploratory study of the psychosocial impact of donating haematopoietic stem cells on adult sibling donors INCB 39110-301 / GRAVITAS A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease INTEGRATE Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE) REACH 2 A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation South Australia JAZZ VOD A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant SHIRE SHP620 A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients Western Australia INTEGRATE A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD) MSC STUDY A phase 2 trial of standard of care treatment versus mesenchymal stromal cell therapy together with standard of care treatment for the treatment of de novo grades 2-4 acute graft versus host disease following allogeneic bone marrow transplantation New Zealand EARLY PARENTERAL NUTRITION IN BMT PATIENTS Early Parenteral Nutrition in BMT Patients GRAVITAS 301 GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease SHIRE CMV A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients